mdxhealth FIRST LOOK: New test added to the menu

mdxhealth continues its growth trajectory as it adds a non-invasive prostate cancer test for risk stratification to its test menu. We deem the asset to be relatively mature as NCCN guidelines and reimbursement are already in place, allowing for topline contribution as of 2H24. Management confirmed no balance sheet impact and no additional capabilities need to be developed. We plan to incorporate the test in a future iteration of our model, and for now maintain our $ 6.0 TP and Buy rating.